- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 285/135 - Nitrogen atoms
Patent holdings for IPC class C07D 285/135
Total number of patents in this class: 253
10-year publication summary
|
21
|
19
|
23
|
18
|
13
|
15
|
12
|
8
|
8
|
4
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Takeda Pharmaceutical Company Limited | 2708 |
11 |
| Bristol-myers Squibb Company | 4880 |
5 |
| Boehringer Ingelheim International GmbH | 4642 |
5 |
| Abbott Laboratories | 2402 |
5 |
| Plexxikon Inc. | 151 |
5 |
| Sanofi | 4072 |
5 |
| The Regents of the University of California | 19961 |
4 |
| The Arizona Board of Regents on Behalf of the University of Arizona | 2165 |
4 |
| Romark Laboratories L.C. | 52 |
4 |
| Vivoryon Therapeutics N.V. | 44 |
4 |
| Synhale Therapeutics Inc. | 4 |
4 |
| Novartis AG | 10744 |
3 |
| Board of Regents, The University of Texas System | 5808 |
3 |
| The Johns Hopkins University | 5675 |
3 |
| Purdue Research Foundation | 3629 |
3 |
| Asceneuron SA | 26 |
3 |
| Betagenon AB | 22 |
3 |
| Dompé Farmaceutici S.p.A. | 266 |
3 |
| The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | 117 |
3 |
| Neuropore Therapies, Inc. | 38 |
3 |
| Other owners | 170 |